MLICM
RNAM

Metropolitan Life Insurance Company (MetLife)’s Avidity Biosciences RNAM Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,869
Closed -$98.7K – 1690
2024
Q1 		$98.7K Hold
3,869
– – ﹤0.01% 1058
2023
Q4 		$35K Hold
3,869
– – ﹤0.01% 1631
2023
Q3 		$24.7K Hold
3,869
– – ﹤0.01% 1791
2023
Q2 		$42.9K Buy
3,869
+338
+10% +$4.24K ﹤0.01% 1507
2023
Q1 		$54.2K Buy
3,531
+220
+7% +$4.84K ﹤0.01% 1342
2022
Q4 		$73.5K Buy
3,311
+339
+11% +$5.05K ﹤0.01% 1236
2022
Q3 		$48.5K Hold
2,972
– – ﹤0.01% 1476
2022
Q2 		$43.2K Buy
2,972
+764
+35% +$11.4K ﹤0.01% 1596
2022
Q1 		$40.8K Sell
2,208
-7,161
-76% -$122K ﹤0.01% 1712
2021
Q4 		$223K Hold
9,369
– – ﹤0.01% 1955
2021
Q3 		$231K Hold
9,369
– – ﹤0.01% 1958
2021
Q2 		$232K Buy
9,369
+421
+5% +$9.79K ﹤0.01% 2040
2021
Q1 		$195K Buy
8,948
+3,871
+76% +$94.8K ﹤0.01% 2035
2020
Q4 		$130K Hold
5,077
– – ﹤0.01% 2219
2020
Q3 		$143K Buy
+5,077
New +$147K ﹤0.01% 1998

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RNAM Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Avidity Biosciences (RNAM) in Q2 2024, closing a stake of 3,869 shares — an estimated $98.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RNAM in Q3 2020 and held it in 15 quarters. The position peaked at $232K in Q2 2021. 196 funds tracked by Wall St. Rank hold RNAM as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Avidity Biosciences position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,869 Avidity Biosciences shares in Q2 2024, an estimated $98.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Avidity Biosciences in Q3 2020 and held it in 15 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Avidity Biosciences position peaked at $232K in Q2 2021.
  • 196 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.